Literature DB >> 12724209

Unanswered questions about the role of promoter methylation in carcinogenesis.

Timothy H Bestor1.   

Abstract

It has been proposed that tumor suppressor genes can be silenced by ectopic de novo methylation during tumor progression and that this epigenetic silencing is an alternative to mutation in tumor suppressor inactivation during oncogenic transformation. However, methylation may follow inactivation and may not directly participate in tumor progression. There are no genetic data that implicate ectopic de novo methylation in cancer, and no DNA methyltransferase gene has been shown to be mutated in any cancer. Promoter methylation at tumor suppressor loci may be a consequence of transcriptional inactivity imposed by mutations in upstream components of the transcriptional machinery or signal transduction pathways. Current estimates of the importance of epigenetic changes in the etiology of cancer may be inflated, and consequences may have been mistaken for causes in some cases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724209     DOI: 10.1111/j.1749-6632.2003.tb05959.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  17 in total

1.  Altered promoter nucleosome positioning is an early event in gene silencing.

Authors:  Luke B Hesson; Mathew A Sloane; Jason Wh Wong; Andrea C Nunez; Sameer Srivastava; Benedict Ng; Nicholas J Hawkins; Michael J Bourke; Robyn L Ward
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

Review 2.  Epigenetic aberrations during oncogenesis.

Authors:  Maria Hatziapostolou; Dimitrios Iliopoulos
Journal:  Cell Mol Life Sci       Date:  2011-01-20       Impact factor: 9.261

3.  Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression.

Authors:  Miguel A López-Lago; Venkata J Thodima; Asha Guttapalli; Timothy Chan; Adriana Heguy; Ana M Molina; Victor E Reuter; Robert J Motzer; Raju S K Chaganti
Journal:  Cancer Res       Date:  2010-10-15       Impact factor: 12.701

4.  Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

Authors:  Albert G Tsai; Haihui Lu; Sathees C Raghavan; Markus Muschen; Chih-Lin Hsieh; Michael R Lieber
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

5.  The effect of interspecific oocytes on demethylation of sperm DNA.

Authors:  Nathalie Beaujean; Jane E Taylor; Michelle McGarry; John O Gardner; Ian Wilmut; Pasqualino Loi; Grazyna Ptak; Cesare Galli; Giovanna Lazzari; Adrian Bird; Lorraine E Young; Richard R Meehan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

Review 6.  Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host.

Authors:  Winston Timp; Andrew P Feinberg
Journal:  Nat Rev Cancer       Date:  2013-06-13       Impact factor: 60.716

Review 7.  Breast cancer epigenetics: normal human mammary epithelial cells as a model system.

Authors:  Rebecca A Hinshelwood; Susan J Clark
Journal:  J Mol Med (Berl)       Date:  2008-08-21       Impact factor: 4.599

8.  Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing.

Authors:  Heinz G Linhart; Haijiang Lin; Yasuhiro Yamada; Eva Moran; Eveline J Steine; Sumita Gokhale; Grace Lo; Erika Cantu; Mathias Ehrich; Timothy He; Alex Meissner; Rudolf Jaenisch
Journal:  Genes Dev       Date:  2007-12-01       Impact factor: 11.361

9.  Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns.

Authors:  Duncan Sproul; Robert R Kitchen; Colm E Nestor; J Michael Dixon; Andrew H Sims; David J Harrison; Bernard H Ramsahoye; Richard R Meehan
Journal:  Genome Biol       Date:  2012-10-03       Impact factor: 13.583

Review 10.  Genomic insights into cancer-associated aberrant CpG island hypermethylation.

Authors:  Duncan Sproul; Richard R Meehan
Journal:  Brief Funct Genomics       Date:  2013-01-21       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.